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Abstract 
A novel hydrazone, (E)-Ethyl-4-(2-(furan-2-ylmethylene)hydrazinyl)benzoate (EFHB), 
has been synthesized and characterized by FT-IR, NMR and Mass spectroscopy, and X-
ray diffraction; compound crystallized as translucent light yellow thin plates. EFHB was 
studied for their binding to human serum albumin (HSA) using the fluorescence quench 
titration method. Molecular docking was also performed to get a more detailed insight 
into their interaction with HSA at the binding site. Addition of this hydrazone to HSA 
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produced significant fluorescence quenching and splitting of emission spectra of HSA 
through static quenching mechanism with binding constants of about 10
4
 M
-1 
at 292.15, 
298.15, 304.15 and 310.15 K. According to the synchronous fluorescence, tryptophan 
and tyrosine residues of the protein are most perturbed by the binding process. 
Thermodynamic parameters ΔG, ΔH, and ΔS were got and the main sort of acting force 
between EFHB and HSA was studied. Results of molecular docking have shown that 
EFHB binds to subdomain IIA of HSA mainly by hydrophobic interaction, energy 
binding are in good agreement with those obtained by fluorescence study (ΔGthe = -7.32 
± 0.09 kcal mol
-1
 and ΔGexp = -6.76 ± 0.03 kcal mol
-1
). 
Keywords: Hydrazone derivative, crystal structure, HSA, molecular docking, 
fluorescence spectroscopy. 
1. Introduction 
Hydrazones and their derivatives have been under study for a long time due to their ease 
preparation, increased hydrolytic stability relative to imines, and its tendency toward 
crystallinity. In addition, this kind of compound is a versatile class to building blocks 
for the synthesis of heterocyclic compounds, drug design, as possible ligands for metal 
complex. Have shown potential applications due to their broad spectrum of biological 
activity, including antitumor, antiviral, vasodilators, antimalarial, anti-inflammatory, 
analgesic, anticonvulsants activities.[1–3] 
In the literature, synthesis of hydrazone derivatives has been reported in order to study 
their mechanisms of interaction with biomolecules of pharmacological interest such as 
human serum albumin (HSA) and bovine serum albumin (BSA), using different 
spectroscopic techniques and methods of molecular modeling. The interaction between 
the hydrazone derivatives N′-(2,4-dimethoxybenzylidene)-2-hydroxybenzohydrazide 
(DBH), 4-chloro- N′-(pyridin-2-ylmethylene)benzohydrazide (CPBH), 2-hydroxy-N′-(3-
hydroxybenzylidene) benzohydrazide (HHB), N′-(4-bromobenzylidene)-2-
hydroxybenzohydrazide (BBH), N′-benzylidene-2-hydroxybenzohydrazide (BH) and 
HSA/BSA have been investigated systematically by fluorescence, These hydrazone 
derivatives form stable complexes with HSA and BSA with binding constants of 10
4
-
10
5
 L mol
-1
.[4–7]  
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HSA in the major protein in human bloodstream and accounts for almost 60% of total 
plasma protein content. HSA is composed of a single polypeptide chain containing 585 
amino acids residues, is stabilized by 17 disulphide bridges, and has a molecular weight 
of 66 kDa. Serum albumin functional activity is essential for maintaining normal tissue 
and organ homeostasis, HSA is the main transporting protein for ligands due to its 
ability to bind to a broad range of both hydrophobic and hydrophilic molecules, 
including drugs (endogenous and exogenous ligands present in blood).[8–11] HSA, is a 
key regulator of fluid movement between plasma and interstitial compartments under 
physiological conditions.[12] Due to these characteristics, HSA is generally used as an 
important model protein in the various studies of biophysics and biochemistry, and one 
of the techniques used is measurement of quenching of albumin’s natural fluorescence 
by drugs for its high sensitivity, rapidity and ease of implementation.[13,14] 
In this article, we report the synthesis and molecular structure of novel hydrazone 
EFHB, together with biophysical studies of its interaction with HSA by fluorescence 
spectroscopy and molecular modeling methods.  
2.- Experimental Methods 
2.1. Chemicals. 
The Western Hematological Institute and Blood Bank of Zulia State, Bolivarian 
Republic of Venezuela supplied human serum albumin (HSA). All other chemicals used 
were of analytical reagent grade. 
2.2. Apparatus. 
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Melting point was determined on a digital IA-9100 ELECTROTHERMAL Fusiometer.  
IR spectrum was recorded on a Shimadzu FTIR-Prestige21 (IR) spectrophotometer, as 
KBr pellets. Spectrophotometer NMR “Brukerbiospin 500” (500 MHz 1H y 125 MHz 
13
C polinuclear) using TMS like reference patron. Mass spectrophotometer Thermo, 
model TQS (quadrupole triple). X-ray diffractometer “Bruker Kappa Apex II Duo”, 
with double wavelength (Cu Ka(alfa) = 1.54; MoKa = 0.71) graphite monochromator 
and area detector. UV-vis spectrometer Shimadzu model UV-3101PC with multi-
chamber compartment and temperature control by Peltier effect. Fluorescence 
measurements were made on a Shimadzu RF-5301PC Fluorospectrophotometer 
equipped with xenon lamp source and 1.0cm*1.0cm*4.0cm quartz cell and a thermostat 
bath.  
2.3. Synthesis of EFHB. 
In a 100 mL round bottom flask, 1.24 g (4.62 mmol) of ethyl 4-hydrazinylbenzoate 
hydrochloride (1) was dissolved in 50 mL of distilled water under magnetic stirring. 
Then, 460 µL (5.54 mmol) of furan-2-carbaldehyde (2) were added slowly, stirring for 
about 20 min after the addition of the furan-2-carbaldehyde (2) (Scheme 1). The product 
was collected by filtration, washed with two aliquots of 10mL 0.1 M HCl and then with 
20 % NaHSO3. The product was recrystallized in ethanol.[15] 
O
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H
2
O
(EFHB)
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O
N
H
N
H
O
(1)
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Scheme 1. Synthesis of EFHB.[16] 
2.4. X-ray single-crystal crystallography. 
Crystal data, data collection and structure refinement details are summarized in Table 1: 
standard software was used throughout.[17–19] All H atoms were located in difference 
maps. The H atoms bonded to C atoms were then treated as riding atoms in 
geometrically idealised positions with C-H distances 0.93 Å (alkenyl, aromatic and 
furanyl), 0.96 Å (-CH3) or 0.97Å (-CH2-), and with Uiso(H) = kUeq(C), where k = 1.5 
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for the methyl group, which was permitted to rotate but not to tilt, and 1.2 for all other 
H atoms bonded to C atoms. For the H atom bonded to atom N41, the atomic 
coordinates were refined with Uiso(H) = 1.2Ueq(N), giving an N-H distance of 0.857(18) 
Å. 
Table 1. Crystal data and refinement for compound EFHB. 
EFHB  
Crystal data 
Chemical formula C14H14N2O3 
Mr 258.27 
Crystal system, space 
group 
Monoclinic, P21/c 
Temperature (K) 296 
a, b, c (Å) 8.3132 (2), 22.8241 (5), 7.4106 (2) 
β (°) 106.359 (1) 
V (Å
3
) 1349.17 (6) 
Z 4 
Radiation type Cu Kα 
μ (mm-1) 0.75 
Crystal size (mm) 0.51 × 0.48 × 0.18 
 
Data collection 
Diffractometer Bruker APEX-II CCD 
Absorption correction Multi-scan  
SADABS (Bruker, 2009) 
 Tmin, Tmax 0.698, 0.874 
No. of measured, 
independent and 
 observed [I > 2σ(I)] 
reflections 
7333, 1967, 1729 
Rint 0.024 
θmax (°) 59.6 
(sin θ/λ)max (Å
-1
) 0.559 
 
Refinement 
R[F
2
 > 2σ(F2)], wR(F2), S 0.035,  0.098,  1.05 
No. of reflections 1967 
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No. of parameters 176 
H-atom treatment H atoms treated by a mixture of independent and constrained 
refinement 
max, min (e Å
-3
) 0.12, -0.19 
 
2.5. Sample preparation and fluorescence quenching measurements. 
An assay solution were prepared by adding appropriate amount HSA in Britton-
Robinson buffer pH = 7.4, the concentration of HSA was determined by UV-vis 
spectroscopy using its molar absorptivity ε280 = 35219 cm
-1
 M
-1
.[10,20,21] Ligand 
EFHB was dissolved in 50% w/v polyethylene glycol (PEG 3350, see figure S1, 
Supporting information). A solution of 2500 µL of [HSA] = 5.0 x 10
-6 
mol L
-1
 was 
added in a 1 cm cell and then titrated with successive additions of [EFHB] = 3.37 x 10
-4 
mol L
-1
 (10 aliquots of 20 µL each until obtaining a volume of a total solution of 2700 
µL). For each addition of EFHB the resulting solution was stirred for 5 minutes before 
measuring to reach equilibrium. Fluorescence emission spectra were measured at 
different temperatures (292.15, 298.15, 304.15 and 310.15 K) and recorder in the 
wavelength range 290-500 nm by exciting HSA at 283 nm. Excitation and emission slits 
were 5 nm, the white correction was carried out by subtracting the emission spectrum 
form the medium used (Britton-Robinson buffer pH = 7.4).[10,21,22] 
2.6. Molecular Docking. 
Molecular docking study was carried out using AutoDock Vina to calculate the possible 
conformation of the ligand EFHB into HSA, and the graphical user interface Auto-
DockTools (ADT 1.5.6).[23] The X-ray crystallography structure of HSA (PDB ID: 
2BXM) it was obtained from the Protein Data Bank.[24] All water and ligands 
molecules present in the biomolecule were removed. Polar hydrogen’s were added to 
the protein structure using AutoDockTools (ADT). To recognize the binding sites in 
HSA, docking was performed by using a box size of 12x22x12 Å with 1 Å grid 
spacing.[24] Cluster analysis was applied on the docked results using a rmsd-tolerance 
of 2.0 Å. ADT program was used to analyze amino acid residues involved in the 
binding between HSA and EFHB, in the best binding site.[24,25] The structure of 
EFHB was generated by ChemSketch package.[16] The geometry of the ligand was 
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optimized without restriction of symmetry by semiempirical methods using the 
Hamiltonian PM6 implemented in the software Gaussian03W (Version B.03).[19,20]  
3. Results and discussion 
3.1. Synthesis and spectroscopic characterization of EFHB. 
The compound EFHB was synthesized from the condensation between the ethyl 4-
hydrazinylbenzoate hydrochloride (1) and furan-2-carbaldehyde (2) (Scheme 1) as 
described above (section 2.3). Yield = 80%, translucent light yellow plates, m.p. = 168-
172 ºC. FT-IR (KBr) cm
-1
: 3259.5 (NH); 1701.1 (C=O); 1678.0 (N=C), 1598.9 (C=C); 
1305.7 (C-O-C); 
1
H NMR (DMSO-d6, 500 MHz): δ 1.28 (t, 3H, -CH3); 4.21 (q, 2H, -
CH2-); 6.57 (dd, 1H, J1 = 3.4, J2 = 1.4 Hz, H44); 6.73 (d, 1H, J = 3.4 Hz, H43); 7.03 (d, 
2H, J = 8.8 Hz, H3 and H5); 7.74 (d, 1H, J = 1.4 Hz, H45); 7.81 (d, 2H, J = 8.8 Hz, H2 
and H6); 7.84 (s, 1H, N=C-H); 10.80 (s, 1H, N-H); 
13
C NMR (DMSO-d6, 125 MHz,): δ 
14.3; 59.8; 110.5; 111.2; 111.9; 119.4; 129.7; 130.9; 143.8; 148.8; 150.2; 165.6; MS: M 
+ 1 = 259.11. 
3.2. Structure description. 
The non-H atoms in the molecule of EFHB (Figure 1) are very nearly coplanar. For the 
atoms in the portion between atom N41 and atom C13, the rms deviation from their 
mean plane is 0.056 Å, with the maximum individual deviation being 0.1073 (14) Å for 
atom C13: for the portion of the molecule between atom N41 and the furanyl ring, the 
rms deviation from their mean plane is only 0.018 Å, with the largest individual 
deviation of 0.0238(13) Å for atom C42. The dihedral angle between the mean planes 
through these portions of the molecule is 7.16(7)
o
. The bond lengths and angles present 
no unusual values: all are consistent with the corresponding values found for 22 
examples of phenylhydrazones found in the Cambridge Structural Database (CSD) [28]. 
There is a short intramolecular C-H...O contact but this cannot be regarded as a 
hydrogen bond as the C-H...O angle is only 100
o
, so that the interaction energy is likely 
to be negligible [29]: in addition the ethyl O atom O12 is likely to be, at best, a rather 
weak acceptor. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
8 
 
 
Figure 1. The molecular structure of EFHB showing the atom-labelling scheme.  
Displacement ellipsoids are drawn at the 30% probability level. 
The 2-thienyl analogue of EFHB (CSD refcode XIGHUS) is in fact isomorphous with 
EFHB, with a volumetric isostructurality index value of 97.7% [15,28,30]: in addition 
XIGHUS turns out to exhibit exactly, the same pattern of supramolecular aggregation as 
found here for EFHB (see below). The supramolecular assembly of EFHB depends 
upon three hydrogen bonds, one each of N-H...O, C-H...O and C-H...π(arene) types 
(Table 2).  
Table 2.  Parameters (Å, 
o
) for hydrogen bonds and short intramolecular contacts. 
D-H H…A D…A D-H…A Motif 
C2-H2…O12 0.93 2.41 2.7261(18) 100 S(5) 
N41-H41...O11
a
       0.857(18)   2.075(18)    2.9068(17)  164.2(13) C(8) 
C46-H46...O11
a
       0.93           2.57             3.3460(18)  141             C(10 
C6-H6...Cg1
b
           0.93            2.94             3.6237(15)  131                - 
Cg1 represents the centroid of the ring (C1-C6). Symmetry codes: a (1 + x, 0.5 - y, 0.5 + z), b (x, 0.5 - y, -
0.5 + z). 
The N-H...O and C-H...O hydrogen bonds together link molecules related by a glide 
plane to form a C(8)C(10)[R
1
2(6)] chain of rings running parallel to the [201] direction 
(Figure 2) [31]. In addition, the C-H...π(arene) hydrogen bond links molecules also 
related by a glide plane into a chain running parallel to the [001] direction (Figure 3), 
and the combination of these two chain motifs generates a sheet lying parallel to (010) 
(Figure 4), but there are no direction-specific interactions between adjacent sheets. 
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Figure 2. Part of the crystal structure of EFHB sowing the formation of a chain of rings 
built from N-H...O and C-H...O hydrogen bonds and running parallel to the [201] 
direction.  Hydrogen bonds are shown as dashed lines and, for the sake of clarity, the H 
atoms not involved in the motif shown have been omitted. 
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Figure 3. Part of the crystal structure of EFHB sowing the formation of a chain built 
from C-H...π(arene) hydrogen bonds and running parallel to the [001] direction. 
Hydrogen bonds are shown as dashed lines and, for the sake of clarity, the H atoms not 
involved in the motif shown have been omitted. 
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Figure 4. Part of the crystal structure of EFHB sowing the formation of a sheet built 
from N-H...O, C-H...O and C-H...π(arene) hydrogen bonds and lying parallel to (010).  
Hydrogen bonds are shown as dashed lines and, for the sake of clarity, the H atoms not 
involved in the motifs shown have been omitted. 
3.3. Interaction between EFHB and HSA: Influence on the fluorescence spectrum. 
Fluorescence spectroscopy is widely used to determine the nature of the interactions 
between ligands and biomolecules. This technique allows determining the mechanism 
by which the HSA-Ligand association is generated, distances bond of the complex, the 
magnitudes of the association constants and thermodynamic parameters. 
HSA possesses within its molecular structure three kinds of residues of amino acids or 
fluorophores: one residue tryptophan (Trp), eighteen residues of tyrosine (Tyr) and 
thirty-one residues of phenylalanine (Phe). The intrinsic fluorescence of the HSA is 
mainly due to the Trp residue, this biomolecule possesses only one (Trp214), which is 
located in the hydrophobic cavity, subdomain IIA (site I). Fluorescence of Tyr is almost 
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completely quenched for many proteins in their native states because it is dissociated or 
in the presence of amine groups, carboxylate groups, carboxylic acids or Trp residues. 
Phe possesses the property of emitting fluorescence, however, lacks practicality because 
it possesses a very low quantum yield.[8,9] 
Binding of EFHB to HSA was monitored by the change in intrinsic fluorescence 
phenomenon of HSA (fluorophore) in the absence and presence of EFHB (quencher). In 
the present investigation, HSA was excited at a wavelength 283 nm (λex = 283 nm) and 
the maximum fluorescence emission (λmax) was observed at 341 nm (Figure 5). With 
increasing concentrations (0-2.5 x 10
-6
 mol L
-1
) of EFHB, the fluorescence intensity of 
HSA (5.0 x 10
-6
 mol L
-1
) was gradually decreased or quenched.[10] 
All the fluorescence data are corrected for absorption of exciting light (283 nm) and 
emitted light (341 nm) according relationship: 
𝐹𝑐 =  𝐹𝑚 𝑒
(𝐴1+𝐴2)/2          (1) 
Fc and Fm are the corrected and measured fluorescence, respectively. A1 and A2 are the 
absorbance of EFHB at excitation wavelength and emission wavelength, 
respectively.[32–34]  
Figure 5 shows the fluorescence emission spectrum of the HSA in the absence 
(spectrum A) and in the presence of EFHB at different concentrations (B-K spectra) and 
298.15 K of temperature. HSA has a fluorescence emission spectrum with a maximum 
at wavelength of 341 nm in the absence of the ligand, in this graph we can watch clearly 
a decrease in the intensity of the intrinsic emission fluorescence of HSA, with 
quenching HSA fluorescence a hypsochromic displacement of the emission band of 341 
at 316 nm is produced. In addition, a splitting of the emission band is generated which 
results in the formation of a new emission band at 387 nm. 
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Figure 5. Effect of EFHB on the fluorescence emission spectrum of HSA in Britton-
Robinson buffer of pH = 7.4 at 298.15 K. The concentration of EFHB: A) 0.0 mol L
-1
, 
B) 2.7 x 10
-6
 mol L
-1
, C) 5.3 x 10
-6
 mol L
-1
, D) 7.9 x 10
-6
 mol L
-1
, E) 1.0 x 10
-5
 mol L
-1
, 
F) 1.3 x 10
-5
 mol L
-1
, G) 1.5 x 10
-5
 mol L
-1
, H) 1.8 x 10
-5
 mol L
-1
, I) 2.0 x 10
-5
 mol L
-1
, 
J) 2.3 x 10
-5
 mol L
-1
, K) 2.5 x 10
-5
 mol L
-1
; the concentration of HSA is 5.0 x 10
-6
 mol 
L
-1
. 
Abou-Zied and Al-Lawatia, reported the characterization of the binding site of a series 
of hydroxyquinolines (HQs) in HSA and found that these kinds of systems presented 
similar spectral behaviors to those found in this work; Displacements and splitting of 
emission band of HSA were evidenced. According to the researchers, these findings 
were generated as a consequence of selective quenching of Trp214 in HSA by the HQs 
ligands, these quenching in the emission fluorescence produce the unmasking of the 
fluorescence of the Tyr residues.[9] 
HSA has in its molecular structure eighteen residues of Tyr, it is important to note that 
only one of these residues Tyr (Tyr263) and Trp214 are in the pocket IIA (site I). These 
investigators estimated the distances between Tyr residues and Trp214 from the 
crystalline structure of the HSA, finding that the distances between Tyr-Trp residues are 
in the range of 13-35 Å and about 17 Å for the distance Tyr263-Trp214. The critical 
distance at which the 50% energy transfer takes place is 15 Å. Therefore, the probability 
that an energy transfer occurs between the Tyr263-Trp214 residues is high. Thus, upon 
selective quenching of Trp214, fluorescence emission of the Tyr263 residue will no 
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longer be masked and its emission band at a lower wavelength with respect to the 
maximum emission band of the native HSA can be visualized.[35–37] 
The results obtained in this work, suggest that the unmasking of the Tyr263 
fluorescence takes place at a wavelength of 316 nm (Figure 5), as a consequence of the 
selective quenching of the fluorescence emission of Trp214 in the HSA-EFHB 
system.[8] 
3.4. Synchronous fluorescence study of EFHB on the Fluorescence Spectrum of 
HSA. 
Synchronous fluorescence is utilized to characterize the interaction of ligands with 
proteins; with this technique, we can obtain information about the molecular 
microenvironment of the chromophores in the biomolecule. Generally, the difference 
between the emission wavelength and the excitation wavelength (Δλ), reflects the 
spectral nature of the chromophores. When Δλ = 60 nm, the synchronous fluorescence 
spectrum of HSA is characteristic of the Trp residue, whereas when Δλ = 15 nm is 
characteristic of the emission of Tyr residues.[38] 
The intensities of the fluorescence emission spectra for the Trp and Tyr residues in the 
synchronous fluorescence assays are quenched when the concentration of the EFHB 
ligand gradually increases. Maximum in the emission spectrum of Trp residue changes 
from 283 to 280 nm (Figure S2, Supporting information), and the maximum emission 
spectrum of the Tyr changes slightly from 288 to 286 nm (Figure S3, Supporting 
information), these spectral changes towards shorter wavelengths (hypsochromic effect) 
suggest that the polarity in the environment of Trp and Tyr decreases, making the cavity 
that harbors them more hydrophobic and they are less exposed to the solvent when the 
HSA comes into contact with the EFHB ligand.[39,40] 
3.5. HSA fluorescence quenching mechanism. 
The Stern-Volmer equation (Equation 2) it was employed to determine the HSA 
quenching mechanism in presence of the ligand EFHB.[41] Equation 2 describes a 
straight line when graphing the F0/F ratio as a function of [Q] at different temperatures; 
this implies that the mechanism of quenching the intrinsic fluorescence of a 
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biomolecule occurs through a homogeneous process, a static or dynamic 
mechanism.[20,41] 
𝐹𝑜
𝐹
= 1 +  𝐾𝑆𝑉[𝑄] = 1 + 𝑘𝑞𝜏𝑜[𝑄]         (2) 
F0 and F are the fluorescence intensities of the biomolecule in the absence and presence 
quencher respectively, KSV is the Stern-Volmer quenching constant, [Q] is the molar 
concentration of quencher, kq is the quenching rate constant of biological 
macromolecule, τ0 is the average excited state lifetime of HSA without quencher, that is, 
5.78 x 10
-9
 s.[20] By plotting the relation of the fluorescence F0/F against the [Q] a 
straight line is obtained whose slope corresponds to the value of KSV (Figure 6).[10,22] 
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Figure 6. Stern-Volmer plots of EFHB at various temperatures. 
 
In order to define the HSA quenching mechanism, the dependence of KSV on the 
temperature it was evaluated, in the Table 3 it is observed that the value of KSV 
decreases with the increase of the temperature, this tendency can also be observed in 
Figure 6. Therefore, the mechanism of quenching of the HSA fluorescence in the 
presence of EFHB is static, and is due to the formation of a complex, if the temperature 
increases, the value of KSV will decrease because of the weakening of the non-specific 
and specific van der Waals forces place to the formation of the complex. On the other 
hand, the values of the quenching bimolecular constants kq can be estimated from to the 
relation kq = KSV/τ0. This values of kq exceed the value of the controlled collision 
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constant, which is 2.0 x 10
10
 M
-1
 s
-1
.[20,34] In the present work, the value of kq for 
HSA-EFHB system is greater than the limiting diffusion rate constant of the 
biomolecule, which indicates that the probable quenching mechanism of HSA in the 
presence of EFHB is initiated by ground state complex formation rather than by 
dynamic collision (Table 3).[22,42] 
Table 3. Binding parameters of HSA-EFHB complex at 292.15, 298.15, 304.15 and 
310.15 K obtained from fluorescence quenching experiments. 
Fluorescence quenching 
experiments parameters 
292.15 K 298.15 K 304.15 K 310.15 K 
KSV (Stern-Volmer constant, M
-1
) 13.81 ± 0.47 x 10
4 
12.63 ± 0.20 x 10
4
 12.31 ± 0.11 x 10
4
 10.63 ± 0.08 x 10
4
 
kq (bimolecular quenching rate 
constant, M
−1
 s
−1
) 
2.39 ± 0.08 x 10
13
 2.18 ± 0.03 x 10
13
 2.13 ± 0.02 x 10
13
 1.84 ± 0.01 x 10
13
 
Ka (binding constant, M
−1
) 10.05 ± 0.33 x 10
4
 9.15 ± 0.26 x 10
4
 6.91 ± 0.26 x 10
4
 9.35 ± 0.84 x 10
4
 
n (binding stoichiometry,  HSA: 
EFHB) 
1.11 ± 0.01 1.10 ± 0.01 1.17 ± 0.01 1.10 ± 0.01 
ΔG (Gibbs free energy change, kcal 
mol
−1
) 
-6.67 ± 0.03 -6.76 ± 0.03 -6.72 ± 0.04 -7.05 ± 0.05 
The data are the average with standard deviation of three independent trials. 
UV-Vis absorption spectroscopy technique is a simple method to determine structural 
changes due to the formation of complexes. In order to confirm the results obtained by 
Stern-Volmer and quenching bimolecular constant (Table 3), the UV-vis absorption 
spectra of the HSA, EFHB and the HSA-EFHB complex were determined (Figure 
7).[4,22,42,43] Dynamic mechanism only affects the excited states of the fluorophores, 
therefore no change in the absorption spectrum is expected, contrary to this the 
formation of a complex that gives rise to a quenching by mechanism static should 
manifest itself with changes in the absorption spectrum of the biomolecule.[35,37] 
Figure 7 shows the HSA absorption spectrum (spectrum A, maximum absorbance at 
280 nm), the resulting spectrum from the subtraction of the EFHB spectrum (spectrum 
C) to the absorption spectrum of the HSA-EFHB complex (Spectrum B), that showed 
an increase in the absorption intensity over the range of the absorption spectrum studied 
(250 to 500 nm, spectrum D) with respect to the spectrum of HSA in the absence of 
EFHB. Spectral changes found by the UV-Vis spectroscopic technique confirm the 
presence of complex formation. Therefore, the process of quenching the fluorescence of 
HSA interacting with EFHB is mediated primarily by a static mechanism.[4,5,44–46]  
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Figure 7. UV-vis absorption spectra of A) HSA, B) HSA + EFHB, C) EFHB and D) 
(HSA + EFHB) – EFHB; [HSA] = [EFHB] = 5.0 x 10-6 M. 
 
3.6. Association constant and number of interaction sites. 
As discussed above, the observed fluorescence quenching is typical static quenching, a 
modified Stern-Volmer equation (Equation 3) is applied to determine the affinity 
constant (Ka) for the system HSA-EFHB.[44,47]  
𝐹𝑂
𝛥𝐹
 =  
𝐹𝑂
𝐹𝑂 − 𝐹 
 =  
1
𝑓𝑎𝐾𝑎
 
1
[𝑄]
 +  
1
𝑓𝑜
          (3) 
Here, fa stands for the fraction of accessible fluorescence and Ka is the effective 
quenching constant. F0 and F are the corrected emission intensity of HSA in the absence 
and presence of quencher [Q] respectively, F0/ΔF is linear with the reciprocal value of 
the quencher concentration [Q] (Figure 8), with slope equal to the value of (faKa)
-1
. Ka 
can be obtained from the intercept and slope. The corresponding values of Ka are listed 
in Table 3.[47] The Ka values for EFHB are 10
4
 L mol
-1
, suggesting very strong binding 
to HSA at the range of temperature studied. The Ka values obtained in the present study 
are consistent with previous literature reports to systems HSA-Hydrazones.[4–7]  
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Figure 8. The plots of F0/F Vs 1/[Q] for EFHB binding with HSA at various 
temperatures. 
The number of bound complex HSA-EFHB (n) were determined by plotting the double 
log graph of the fluorescence data using.[47] Plotting log((F0 – F)/F) Vs log[Q] 
according to equation 4, it was obtained a straight line whose slope denotes the number 
of interaction sites that may have in the formation of the HSA-EFBH complex (Figure 
9).[42,43] The number of interaction sites for HSA-EFHB complex at different 
temperatures is approximately n = 1 (Table 3), meaning that only one molecule of the 
EFHB binds to one HSA molecule.[47] 
𝑙𝑜𝑔
𝐹𝑂 −  𝐹
𝐹
= 𝑙𝑜𝑔𝐾 +  𝑛𝑙𝑜𝑔[𝑄]         (4) 
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Figure 9. The plots of log((F0 - F)/F) Vs log[Q] for EFHB binding with HSA at various 
temperatures. 
3.7. Thermodynamic parameters. 
Thermodynamic association parameters can be estimated by Gibbs-Helmholtz 
(Equation 5) and Van't Hoff isochore equations (Equation 6); these allow obtaining 
information about the magnitudes and the nature of the bond in the formation of ligand-
biomolecule complexes. There are mainly four types of non-covalent interactions in the 
complex formation between small molecules and biomolecules, as such as hydrogen 
bonds, van der Waals forces, hydrophobic and electrostatic interactions.[32,48]  
Δ𝐺 =  Δ𝐻 − 𝑇Δ𝑆 =  −𝑅𝑇𝑙𝑛𝐾𝑎           (5) 
ln (
Ka2
Ka1
) =  (
1
𝑇1
−
1
𝑇2
)
Δ𝐻
𝑅
          (6) 
ΔG, ΔH and ΔS are the free energy of Giggs, enthalpy and entropy respectively, Ka is the 
constant of association to the temperature T and R is the constant of the gases. Ross and 
Subramanian reported an analysis of the thermodynamic parameters associated with the 
different types of interaction that can take place in the formation of ligand-biomolecule 
complexes.[48] The authors showed that, when:  
 ΔH < 0 or ΔH ≅ 0 and ΔS > 0, the electrostatic forces are mainly involved in the 
complex formation process. 
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 ΔH < 0 and ΔS < 0, the interaction is dominated mainly by van der Waals forces 
or by hydrogen bonds. 
 ΔH > 0 and ΔS > 0, the main interaction forces that give rise to the formation of 
the complex are the hydrophobic ones. 
In this work, all HSA-EFHB association processes in the temperature range studied 
were spontaneous (Table 3). In the process of formation of the EFHB-HSA complex 
from 292.15 to 298.15 K it presented a ΔH = -2.72 kcal mol-1 and ΔS = 13.55 cal mol-1 
K
-1
, to the process from 298.15 to 304.15 K the values of ΔH was -5.50 kcal mol-1 and 
ΔS = 4.02 cal mol-1 K-1, therefore, the process to the formation of the complex was more 
exothermic and with less favorable steric factors to the previous binding process 
(292.15-298.15 K), and into the increased temperature from 304.15 to 310.15 K, the 
values of ΔH and ΔS were -0.72 kcal mol-1 and 20.43 mol cal-1 K-1 respectively, for this 
case, the bonding process happened to be less exothermic and to be favored or sterically 
driven.[10,32,48]  
Table 4. Thermodynamic parameters of the HSA-EFHB interaction at different 
temperatures. 
Temperature (K) ΔH (kcal mol-1) ΔG (kcal mol-1) ΔS (cal mol-1 K-1) 
292.15-298.15 -2.72 -6.76 13.55 
298.15-304.15 -5.50 -6.72 4.02 
304.15-310.15 -0.72 -7.05 20.43 
 
According to Ross and Subramanian, the association between HSA and EFHB in the 
temperature range studied is mainly mediated by electrostatic interactions, ΔH < 0 and ΔS 
> 0.[48] 
3.8. Molecular modeling. 
In this study, molecular docking was used to predict the binding constant and binding’s 
site on HSA-EFHB complex to confirm the results of the experimental measurements 
described earlier, and to identify the main amino acid residues as well as the principal 
forces involved in the association HSA-EFHB. The best conformation of ligand with 
lowest binding-free energy (-7.32 kcal mol
-1
) was in the subdomain IIA (Figure 10). 
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Figure 10. a) Union site, b) Specific and non-specific interactions and c) Interactions π-
π of EFHB-HSA complex. 
Molecular docking results also suggested hydrophobic and electrostatic interactions as 
the main binding forces, which is in accord to the experimental data. The complex 
HSA-EFHB is stabilized by stacking π...π with the residue Trp214 (distance 3.703 Å). 
On the other hand, EFHB is stabilized into HSA by hydrophobic interaction with the 
residues Lys199, Ser202, Ala210 and Ala215, Phe211, Arg218 and Leu238 (Figure 12). 
The calculated binding Gibbs, was ΔG = -7.32 kcal mol-1; while the experimental data 
was -6.79 kcal mol
-1
, this can be attributed to the differences between the X-ray 
structures of the protein from crystals to the aqueous system used in this study. 
 
6. Conclusions 
This paper describes the synthesis and characterization of the substituted 
phenylhydrazone derivative EFHB using different spectroscopic techniques, along with 
a single-crystal X-ray structure, and the reaction between of HSA and EFHB which was 
investigated using spectroscopic fluorescence and molecular modeling methods. The 
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intrinsic fluorescence of HSA was quenched by EFHB with static quenching 
mechanism. The association constants, number of binding sites and thermodynamic 
parameters were determined at different temperatures. In addition, binding site was 
located at the subdomain IIA of HSA. The binding study of drugs with proteins is of 
great importance in pharmacy, pharmacology, and biochemistry. This study is expected 
to provide important insight into the interactions of the physiologically important 
protein HSA with drugs. 
Acknowledgments 
 
The authors thank Fondo Nacional de Ciencia, Tecnología e Innovación (FONACIT 
Proyecto de apoyo a Grupos No. G-2005000403). Proyecto 1063, Instituto Venezolano 
de Investigaciones Científicas (IVIC).  
 References 
 
[1] N.P. Belskaya, W. Dehaen, V.A. Bakulev, Synthesis and properties of 
hydrazones bearing amide, thioamide and amidine functions, Arkivoc. 2010 
(2010) 275–332. doi:10.3998/ark.5550190.0011.108. 
[2] A.-Z.A. Elassar, H.H. Dib, N.A. Al-Awadi, M.H. Elnagdi, Chemistry of 
carbofunctionally substituted hydrazones., Ark. (Gainesville, FL, United States). 
2007 (2007) 272–315. doi:10.3998/ark.5550190.0008.210. 
[3] S. Rollas, Ş.G. Küçükgüzel, Biological activities of hydrazone derivatives, 
Molecules. 12 (2007) 1910–1939. doi:10.3390/12081910. 
[4] F.F. Tian, F.L. Jiang, X. Le Han, C. Xiang, Y.S. Ge, J.H. Li, Y. Zhang, R. Li, 
X.L. Ding, Y. Liu, Synthesis of a novel hydrazone derivative and biophysical 
studies of its interactions with bovine serum albumin by spectroscopic, 
electrochemical, and molecular docking methods, J. Phys. Chem. B. 114 (2010) 
14842–14853. doi:10.1021/jp105766n. 
[5] F.F. Tian, J.H. Li, F.L. Jiang, X. Le Han, C. Xiang, Y.S. Ge, L.L. Li, Y. Liu, The 
adsorption of an anticancer hydrazone by protein: An unusual static quenching 
mechanism, RSC Adv. 2 (2012) 501–513. doi:10.1039/c1ra00521a. 
[6] J.Q. Tong, F.F. Tian, Q. Li, L.L. Li, C. Xiang, Y. Liu, J. Dai, F.L. Jiang, Probing 
the adverse temperature dependence in the static fluorescence quenching of BSA 
induced by a novel anticancer hydrazone, Photochem. Photobiol. Sci. 11 (2012) 
1868–1879. doi:10.1039/c2pp25162k. 
[7] J.Q. Tong, F.F. Tian, Y. Liu, F.L. Jiang, Thermodynamic properties of the site-
selective binding of a bromo-hydrazone and its unsubstituted analogue to human 
serum albumin, J. Solution Chem. 44 (2015) 193–205. doi:10.1007/s10953-015-
0303-7. 
[8] O.K. Abou-Zied, O.I.K. Al-Shihi, Characterization of Subdomain IIA Binding 
Site of Human Serum Albumin in its Native, Unfolded, and Refolded States 
Using Small Molecular Probes, J. Am. Chem. Soc. 130 (2008) 10793–10801. 
doi:10.1021/ja8031289. 
[9] O.K. Abou-Zied, N. Al-Lawatia, Exploring the Drug-Binding Site Sudlow I of 
Human Serum Albumin: The Role of Water and Trp214 in Molecular 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
23 
 
Recognition and Ligand Binding, ChemPhysChem. 12 (2011) 270–274. 
doi:10.1002/cphc.201000742. 
[10] S. Bi, L. Yan, Y. Sun, H. Zhang, Investigation of ketoprofen binding to human 
serum albumin by spectral methods, Spectrochim. Acta Part A Mol. Biomol. 
Spectrosc. 78 (2011) 410–414. doi:10.1016/j.saa.2010.11.002. 
[11] M. Bagheri, M.H. Fatemi, Fluorescence spectroscopy, molecular docking and 
molecular dynamic simulation studies of HSA-Aflatoxin B1 and G1 interactions, 
J. Lumin. 202 (2018) 345–353. doi:10.1016/j.jlumin.2018.05.066. 
[12] G. Rabbani, M.H. Baig, A.T. Jan, E.J. Lee, M.V. Khan, M. Zaman, A. Farouk, 
R.H. Khan, I. Choi, Binding of erucic acid with human serum albumin using a 
spectroscopic and molecular docking study, Int. J. Biol. Macromol. 12 (2017) 
979–990. doi:10.1016/j.ijbiomac.2017.04.051. 
[13] M. Ishtikhar, G. Rabbani, S. Khan, R.H. Khan, RSC Advances Biophysical 
investigation of thymoquinone binding, RSC Adv. 5 (2015) 18218–18232. 
doi:10.1039/C4RA09892G. 
[14] A. Varshney, M. Rehan, N. Subbarao, G. Rabbani, R.H. Khan, Elimination of 
Endogenous Toxin , Creatinine from Blood Plasma Depends on Albumin 
Conformation : Site Specific Uremic Toxicity & Impaired Drug Binding, PLoS 
One. 6 (2011) e17230. doi:10.1371/journal.pone.0017230. 
[15] M. Morales-Toyo, Y.J. Alvarado, J. Restrepo, L. Seijas, R. Atencio, J. Bruno-
Colmenarez, Synthesis, Crystal Structure Analysis, Small Cluster Geometries and 
Energy Study of (E)-Ethyl-4-(2-(thiofen-2-ylmethylene)hydrazinyl)benzoate, J. 
Chem. Crystallogr. 43 (2013) 544–549. doi:10.1007/s10870-013-0455-5. 
[16] ACD/ChemSketch, Freeware version 10.00, Adv. Chem. Dev. Inc., Toronto, ON, 
Canada. (2006). www.acdlabs.com. 
[17] Bruker, SAINT. Bruker AXS Inc., Madison, Wisconsin, USA., (2009). 
[18] G.M. Sheldrick, Crystal structure refinement with SHELXL, Acta Crystallogr. 
Sect. C Struct. Chem. 71 (2015) 3–8. doi:10.1107/S2053229614024218. 
[19] A.L. Spek, Structure validation in chemical crystallography, Acta Crystallogr. 
Sect. D Biol. Crystallogr. 65 (2009) 148–155. doi:10.1107/S090744490804362X. 
[20] I. Choi, K. Ahmad, M.H. Baig, G. Rabbani, E.J. Lee, Binding of Tolperisone 
Hydrochloride with Human Serum Albumin: Effects on the Conformation, 
Thermodynamics, and Activity of HSA, Mol. Pharm. 15 (2018) 1445–1456. 
doi:10.1021/acs.molpharmaceut.7b00976. 
[21] C.M. Fernández, V.C. Martin, Preparation d’un tampon universel de force 
ionique 0,3 M, Talanta. 24 (1977) 747–748. doi:10.1016/0039-9140(77)80204-X. 
[22] A. Varlan, M. Hillebrand, Bovine and Human Serum Albumin Interactions with 
3-Carboxyphenoxathiin Studied by Fluorescence and Circular Dichroism 
Spectroscopy, Molecules. 15 (2010) 3905–3919. 
doi:10.3390/molecules15063905. 
[23] O. Trott, A.J. Olson, Software News and Update AutoDock Vina: Improving the 
Speed and Accuracy of Docking with a New Scoring Function, Efficient 
Optimization, and Multithreading, J. Comput. Chem. 31 (2010) 455–461. 
doi:10.1002/jcc. 
[24] J. Ghuman, P.A. Zunszain, I. Petitpas, A.A. Bhattacharya, M. Otagiri, S. Curry, 
Structural basis of the drug-binding specificity of human serum albumin, J. Mol. 
Biol. 353 (2005) 38–52. doi:10.1016/j.jmb.2005.07.075. 
[25] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, 
A.J. Olson, CHARMM: The Biomolecular Simulation Program B., J. Comput. 
Chem. 30 (2009) 1545–1614. doi:10.1002/jcc. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
24 
 
[26] Z. Bikadi, E. Hazai, Application of the PM6 semi-empirical method to modeling 
proteins enhances docking accuracy of AutoDock, J. Cheminform. 1 (2009) 1–
16. doi:10.1186/1758-2946-1-15. 
[27]  and D.J.F. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. 
Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, 
H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. 
Zheng, J. L. Sonnenberg, M. Had, Gaussian 09 Rev. D. 01, 01 (2009) 2009. 
[28] C.R. Groom, I.J. Bruno, M.P. Lightfoot, S.C. Ward, feature articles The 
Cambridge Structural Database, Acta Crystallogr. Sect. B Struct. Sci. B72 (2016) 
171–179. doi:10.1107/S2052520616003954. 
[29] P.A. Wood, F.H. Allen, E. Pidcock, Hydrogen-bond directionality at the donor H 
atom — analysis of interaction energies and database statistics, CrystE. 11 (2009) 
1563–1571. doi:10.1039/b902330e. 
[30] L. Fábián, A. Kálmán, Volumetric measure of isostructurality, Acta Crystallogr. 
Sect. B Struct. Sci. 55 (1999) 1099–1108. doi:10.1107/S0108768199009325. 
[31] J. Bernstein, R.E. Davis, L. Shimoni, N. ‐L Chang, Patterns in Hydrogen 
Bonding: Functionality and Graph Set Analysis in Crystals, Angew. Chemie Int. 
Ed. English. 34 (1995) 1555–1573. doi:10.1002/anie.199515551. 
[32] S. Bi, H. Zhang, C. Qiao, Y. Sun, C. Liu, Studies of interaction of emodin and 
DNA in the presence of ethidium bromide by spectroscopic method, 
Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 69 (2008) 123–129. 
doi:10.1016/j.saa.2007.03.017. 
[33] M.S. Ali, H.A. Al-Lohedan, Spectroscopic and computational evaluation on the 
binding of safranal with human serum albumin: Role of inner filter effect in 
fluorescence spectral correction, Spectrochim. Acta - Part A Mol. Biomol. 
Spectrosc. 203 (2018) 434–442. doi:10.1016/j.saa.2018.05.102. 
[34] B.P. Kamat, J. Seetharamappa, In vitro study on the interaction of mechanism of 
tricyclic compounds with bovine serum albumin, J. Pharm. Biomed. Anal. 35 
(2004) 655–664. doi:10.1016/j.jpba.2004.02.008. 
[35] C.B. Berde, B.S. Hudson, R.D. Simoni, L.A. Sklar, Human serum albumin 
spectroscopic studies of binding and proximity relationships for fatty acids and 
bilirubin, J. Biol. Chem. 254 (1979) 391–400. en.m.wikipedia.org/wiki/albumin. 
[36] X.M. He, D.C. Carter, Atomic structure and chemistry of human serum albumin, 
Nature. 358 (1992) 209–215. doi:10.1038/358209a0. 
[37] G. Sudlow, D.J. Birkett, D.N. Wade, The Characterization of Two Specific Drug 
Binding Sites on Human Serum, Mol. Pharmacol. 11 (1975) 824–832. 
[38] J. Peuravuori, R. Koivikko, K. Pihlaja, Characterization, differentiation and 
classification of aquatic humic matter separated with different sorbents: 
synchronous scanning fluorescence spectroscopy, Water Res. 36 (2002) 4552–
4562. doi:10.1016/S0043-1354(02)00172-0. 
[39] Y. Wang, G. Zhang, L. Wang, Interaction of prometryn to human serum albumin: 
Insights from spectroscopic and molecular docking studies, Pestic. Biochem. 
Physiol. 108 (2014) 66–73. doi:10.1016/j.pestbp.2013.12.006. 
[40] X.-M. Zhou, W.-J. Lü, L. Su, Z.-J. Shan, X.-G. Chen, Binding of Phthalate 
Plasticizers to Human Serum Albumin in Vitro: A Multispectroscopic Approach 
and Molecular Modeling, J. Agric. Food Chem. 60 (2012) 1135–1145. 
doi:10.1021/jf204380r. 
[41] M.A. Cheema, P. Taboada, S. Barbosa, J. Juárez, M. Gutiérrez-Pichel, M. Siddiq, 
V. Mosquera, Human serum albumin unfolding pathway upon drug binding: A 
thermodynamic and spectroscopic description, J. Chem. Thermodyn. 41 (2009) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
25 
 
439–447. doi:10.1016/j.jct.2008.11.011. 
[42] B. Chakraborty, S. Basu, Interaction of BSA with proflavin: A spectroscopic 
approach, J. Lumin. 129 (2009) 34–39. doi:10.1016/j.jlumin.2008.07.012. 
[43] P. Daneshgar, A.A. Moosavi-Movahedi, P. Norouzi, M.R. Ganjali, A. Madadkar-
Sobhani, A.A. Saboury, Molecular interaction of human serum albumin with 
paracetamol: Spectroscopic and molecular modeling studies, Int. J. Biol. 
Macromol. 45 (2009) 129–134. doi:10.1016/j.ijbiomac.2009.04.011. 
[44] A.S. Sharma, S. Anandakumar, M. Ilanchelian, In vitro investigation of domain 
specific interactions of phenothiazine dye with serum proteins by spectroscopic 
and molecular docking approaches, RSC Adv. 4 (2014) 36267–36281. 
doi:10.1039/c4ra04630g. 
[45] A.A. Saboury, C. Pillip, S. Riahi, B. Larijani, M. Hosseini, F. Faridbod, M.R. 
Ganjali, P. Norouzi, Interaction study of pioglitazone with albumin by 
fluorescence spectroscopy and molecular docking, Spectrochim. Acta Part A 
Mol. Biomol. Spectrosc. 78 (2010) 96–101. doi:10.1016/j.saa.2010.09.001. 
[46] M.S. Seyed Dorraji, V. Panahi Azar, M.H. Rasoulifard, Interaction between 
deferiprone and human serum albumin: Multi-spectroscopic, electrochemical and 
molecular docking methods, Eur. J. Pharm. Sci. 64 (2014) 9–17. 
doi:10.1016/j.ejps.2014.08.001. 
[47] S. Tabassum, W.M. Al-Asbahy, M. Afzal, F. Arjmand, Synthesis, 
characterization and interaction studies of copper based drug with Human Serum 
Albumin (HSA): Spectroscopic and molecular docking investigations, J. 
Photochem. Photobiol. B Biol. 114 (2012) 132–139. 
doi:10.1016/j.jphotobiol.2012.05.021. 
[48] P.D. Ross, S. Subramanian, Thermodynamics of protein association reactions: 
forces contributing to stability, Biochemistry. 20 (1981) 3096–3102. 
doi:10.1021/bi00514a017. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
26 
 
 
Graphical abstract 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
27 
 
Highlights (EFHB) 
 
.- A new phenylhydrazone derivative was synthesized. 
.- The influence of the EFBH on the emission spectrum of the HSA was studied. 
.- The HSA-EFHB association occurs through a static mechanism or complex 
formation. 
.- The binding site of EFHB in the HSA was studied using molecular modeling. 
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